High Prevalence of Asymptomatic Malaria in a Tribal Population in Eastern India
Open Access
- 1 May 2013
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 51 (5) , 1439-1444
- https://doi.org/10.1128/jcm.03437-12
Abstract
Asymptomatic infection by Plasmodium falciparum is an important obstacle to eliminating malaria. Asymptomatic carriers do not seek treatment for infection, and therefore they become a reservoir for the parasite. For this reason, these carriers pose a real public health risk. The systematic identification and treatment of asymptomatic infections should reduce the parasite reservoir. A large reduction in this pool will lower the chance of transmission of the disease. In this study, we screened a tribal population of 1,040 individuals in the Purulia district of West Bengal by using a dual-antigen rapid diagnostic kit (RDK), microscopy, and species-specific PCR. All positive individuals were treated with artemisinin-based combination therapy (ACT) (artesunate plus sulfadoxine-pyrimethamine) and followed for 42 days. Polymorphisms in candidate genes were screened by DNA sequencing. A significant proportion (8.4%) of the study population was infected with P. falciparum but showed no clinical manifestations. The PCR method was more sensitive in detecting infection than the RDK or microscopy. The efficacy of the ACT was 97%. In the pfcrt gene, the mutation K76T (the mutated amino acid is indicated by bold type) was found in 100% of the cases. In the pfmdr1 gene, the mutations N86Y and Y184F were noted in 55.5% and 11% of the cases, respectively. Six different haplotypes were identified in the pfdhfr-pfdhps genes. Most importantly, the quintuple mutant A 16 I 51 R 59 N 108 I 164 -S 436 G 437 E 540 A 581 A 613 was found in 10% of the isolates, which is potentially important for the development of sulfadoxine-pyrimethamine resistance. A significant proportion of the study population harboring P. falciparum does not seek treatment and therefore serves as a reservoir for the parasite, maintaining the natural cycle. If the National Vector Borne Disease Control Programme (NVBDCP) of India is to eliminate malaria, then this hidden parasite burden needs to be addressed properly. Similar study in other parts of the country could help to determine the magnitude of the problem.Keywords
This publication has 25 references indexed in Scilit:
- Comparative Efficacies of Artemisinin Combination Therapies in Plasmodium falciparum Malaria and Polymorphism of pfATPase6 , pfcrt , pfdhfr , and pfdhps Genes in Tea Gardens of Jalpaiguri District, IndiaAntimicrobial Agents and Chemotherapy, 2012
- Exploring the Contribution of Candidate Genes to Artemisinin Resistance in Plasmodium falciparumAntimicrobial Agents and Chemotherapy, 2010
- Plasmodium falciparumDrug Resistance in Madagascar: Facing the Spread of Unusualpfdhfrandpfmdr-1Haplotypes and the Decrease of Dihydroartemisinin SusceptibilityAntimicrobial Agents and Chemotherapy, 2009
- High Prevalence of AsymptomaticPlasmodium falciparumInfections in a Highland Area of Western Kenya: A Cohort StudyThe Journal of Infectious Diseases, 2009
- Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2)Malaria Journal, 2009
- A country-wide malaria survey in Mozambique. II. Malaria attributable proportion of fever and establishment of malaria case definition in children across different epidemiological settingsMalaria Journal, 2009
- Relation between Plasmodium falciparum asymptomatic infection and malaria attacks in a cohort of Senegalese childrenMalaria Journal, 2008
- Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variantsMalaria Journal, 2008
- Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparumMalaria Journal, 2007
- Gametocytaemia after Drug Treatment of Asymptomatic Plasmodium falciparumPLoS Clinical Trials, 2006